top stories

Lack of de­tail in Trump's drug price plan rais­es more ques­tions than an­swers

7 hours ago
Pharma
Law

Roche could re­think $50B US ex­pan­sion plan if new poli­cies 'har­m' op­er­a­tions

10 hours ago
Pharma
Manufacturing

Phar­ma in­vestors brush off Trump’s ‘most fa­vored na­tion’ plan as stocks rise

7 hours ago
Pharma

Latest

PBM over­haul and drug price ne­go­ti­a­tions make the cut in Re­pub­li­can­s' tax bill

9 hours ago
Pharma
Law

Ex­clu­sive: Patrick Hsu start­up launch­es, looks be­yond CRISPR for gene in­ser­tion tech­nol­o­gy

11 hours ago
Startups
Cell/Gene Tx

Vir’s hep B dis­ap­point­ment, Ipsen's new Iqir­vo da­ta, plus more from #EASL25

12 hours ago
R&D

FDA clears in vi­vo blood stem cell edit­ing tri­al; Abeon­a's $155M PRV sale

12 hours ago
News Briefing
see latest stream
People

AI-fo­cused biotech in­sitro cuts 22% of staff, cit­ing 'tu­mul­tuous mar­ket'

4 days ago

Blood can­cer biotech Vor Bio ends clin­i­cal work, lays off 95% of staff

4 days ago

Eu­rope pledges €500M to at­tract glob­al sci­ence tal­ent

6 days ago
Financing

Chron­ic care start­up Oma­da Health files to go pub­lic

3 days ago

AI biotech In­sil­i­co Med­i­cine goes for third at­tempt at Hong Kong IPO

3 days ago

HAYA Ther­a­peu­tics gets $65M for 'dark genome' work fol­low­ing last year's Lil­ly pact

4 days ago
Startups

Ex­clu­sive: Degra­da­tion start­up rais­es $39M for piv­ot to PRO­TACs and clin­i­cal en­try

6 days ago

Sin­ga­pore car­dio gene ther­a­py biotech col­lects $45M as it plots Eu­rope ex­pan­sion

6 days ago

Func­tion buys Ezra, cre­at­ing one-stop shop for pre­ven­tive test­ing and scans

Last week
Deals

Cedars-Sinai part­ners with Re­design Health to build health tech star­tups

5 days ago

Ex­clu­sive: SEC ex­pect­ed to drop in­ves­ti­ga­tion of Il­lu­mi­na's $8B Grail deal

6 days ago

Af­ter hunt for al­ter­na­tives, Kro­nos Bio se­lects Tang Cap­i­tal's Con­cen­tra for a deal

Last week

In FocusSee all

'Find a way, or make one': How two sci­en­tists hope to re­vi­tal­ize CRISPR's rare dis­ease cri­sis

4 days ago
R&D
Cell/Gene Tx

The in­side sto­ry of how Sali­o­Gen, a start­up try­ing to wran­gle ‘jump­ing genes’ to make med­i­cines, fell apart

Last week
Startups

US drug­mak­ers in­creas­ing­ly look abroad for clin­i­cal tri­als as con­fi­dence in FDA wa­vers

Last week
Pharma

Pri­mate re­searchers cope with un­cer­tain­ty as NIH ap­peals for pay­ment cuts in court 

4 weeks ago
R&D
Pharma

Endpoints Standouts

Will CRISPR mat­ter?

2 months ago
R&D
Special

Big am­bi­tions at Mer­ck and As­traZeneca — along with a few gi­ant pit­falls — re­shape top ranks of the R&D 15

Last month
Bioregnum
R&D

Il­lu­mi­na was built on DNA. Its fu­ture could be bi­ol­o­gy’s next big wave

Last month
In Focus
Diagnostics

Where the mon­ey is: The top 100 ven­ture in­vestors in biotech

2 months ago
Financing
Bioregnum

Peer review See all

May
9

Lil­ly shuf­fles key ex­ec­u­tive po­si­tions; Mikael Dol­sten takes an­oth­er post-Pfiz­er as­sign­ment

May
2

For­mer Tome CEO joins Flag­ship start­up; NGM Bio chief steps down as re­struc­tur­ing takes ef­fect

Apr
25

Paul Stof­fels on re­tir­ing from Gala­pa­gos; Boehringer In­gel­heim switch­es up lead­er­ship

Apr
17

Sarep­ta los­es CMO to RNA edit­ing up­start; An­oth­er wave of per­son­nel moves at Dyne

Apr
11

Ira Mell­man joins PI­CI; Vi­iV Health­care CMO re­places Chris Cor­si­co at GSK

Pharma channel feed

14 hours ago

Up­dat­ed: White House threat­ens ‘most fa­vored na­tion’ plan to low­er US drug prices, but many ques­tions re­main

The White House plans to force down prices of drugs sold in the US by threat­en­ing to tie costs to rates paid by oth­er coun­tries, a di­rec­tive that could have huge im­pacts but is al­most ...

READ MORE

Trump says he'll sign or­der on 'most fa­vored na­tion' drug price plans Mon­day

Yesterday
R&D

Io­vance stock plum­mets af­ter low­ered full-year guid­ance, missed an­a­lyst ex­pec­ta­tions for Am­tagvi

3 days ago
Manufacturing
latest in Pharma

Lon­za says its US-based sites are in high de­mand as phar­ma tar­iffs near

3 days ago
Manufacturing

Il­lu­mi­na con­firms SEC has closed in­ves­ti­ga­tion in­to $8B Grail deal

4 days ago
Diagnostics

Take­da an­nounces hand­ful of pipeline cuts in ef­fort to ‘piv­ot re­sources’

4 days ago

Il­lu­mi­na fore­casts $85M in tar­iff costs, de­crease in Chi­na sales

4 days ago
Diagnostics

As­traZeneca los­es ap­peals court fight over IRA drug price ne­go­ti­a­tions

4 days ago
Law
see latest stories

Marketing channel feed

Last month

HHS says it may re­vis­it an­ti-obe­si­ty drug poli­cies af­ter drop­ping Biden-era pro­pos­al

The gov­ern­ment said it “may con­sid­er fu­ture pol­i­cy op­tions” for an­ti-obe­si­ty med­ica­tions, af­ter de­clin­ing to fi­nal­ize a Biden-era pro­pos­al that would have ex­pand­ed cov­er­age to mil­lions ...

READ MORE

RFK Jr. has long crit­i­cized drug ads. He just slashed the FDA of­fice that reg­u­lates them

Last month
Pharma
FDA+

J&J touts new sur­vival da­ta pit­ting lung can­cer com­bo against As­traZeneca's ri­val

Last month
R&D
Pharma
latest in Marketing

No­vo Nordisk slash­es We­govy price by near­ly two-thirds for cash-pay­ing pa­tients

2 months ago
Pharma

Mis­lead­ing ex­hib­it booth pan­el lands NJ drug­mak­er an un­ti­tled let­ter from FDA

2 months ago
FDA+

Eli Lil­ly ex­pands Zep­bound sin­gle-dose vial op­tions at low­er price

2 months ago
Pharma

J&J's new can­cer com­bo beats As­traZeneca's Tagris­so on sur­vival in lung tri­al

4 months ago
Pharma

Drugs are ap­proved — and made avail­able — faster in US than most of EU, da­ta show

5 months ago
Pharma
FDA+
see latest stories

FDA+ channel feed

4 days ago

GSK awaits Nu­cala de­ci­sion af­ter FDA tar­get date pass­es

The FDA is still re­view­ing a la­bel ex­pan­sion for GSK’s res­pi­ra­to­ry drug Nu­cala in chron­ic ob­struc­tive pul­monary dis­ease de­spite the May 7 tar­get date for a de­ci­sion, the com­pa­ny ...

READ MORE

FDA grants Ve­rastem first ap­proval for rare ovar­i­an can­cer treat­ment

4 days ago
Pharma

FDA will con­vene vac­cine ad­vi­sors to dis­cuss Covid strain up­dates

5 days ago
Pharma
latest in FDA+

FDA's ODAC will re­view drugs for four dif­fer­ent can­cers at meet­ing in May

5 days ago
Pharma

What Vinay Prasad means for CBER, vac­cines, drug ap­provals and more

5 days ago
Pharma

Sarep­ta’s stock plum­mets af­ter Prasad ap­point­ment, low Ele­v­idys sales

6 days ago
Pharma

Trump, FDA ze­ro in on for­eign fac­to­ries to give do­mes­tic sites an edge  

6 days ago
Pharma
Manufacturing

FDA picks con­tro­ver­sial doc­tor Vinay Prasad as CBER di­rec­tor, in about-face from Marks

6 days ago
see latest stories

Manufacturing channel feed

4 days ago

Bris­tol My­er­s' $40B US in­vest­ment; Sh­iono­gi to buy Japan­ese drug­mak­er

Wel­come to End­points News’ man­u­fac­tur­ing briefs, where we bring you es­sen­tial news on new builds, col­lab­o­ra­tions, re­calls and more.

READ MORE

Gilead re­veals plans to put an­oth­er $11B in­to US man­u­fac­tur­ing

5 days ago
R&D
Pharma

Te­va plans staff cuts as it com­mits to ac­cel­er­at­ing growth

5 days ago
Pharma
latest in Manufacturing

PhRMA says tar­iffs are 'not the an­swer' as in­dus­try trade probe clos­es for com­ments

5 days ago
Pharma

Charles Riv­er launch­es ‘strate­gic re­view’ along­side ac­tivist in­vestor El­liott

5 days ago
Outsourcing

In­vestors un­veil plans for $1.3B can­cer hub in Lon­don sub­urbs

Last week
R&D

Bris­tol My­ers to close cell ther­a­py site in Illi­nois as part of on­go­ing cost cuts

Last week
People
Cell/Gene Tx

Lil­ly CEO Ricks urges Trump to drop drug tar­iff plan

Last week
Pharma
see latest stories
A service from the Financial Times